Cardlytics Inc (NASDAQ:CDLX) Given Average Recommendation of “Hold” by Brokerages

Cardlytics Inc (NASDAQ:CDLX) has been given an average recommendation of “Hold” by the eleven analysts that are currently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, four have assigned a hold recommendation and four have issued a buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $47.60.

A number of research firms recently issued reports on CDLX. ValuEngine raised shares of Cardlytics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Craig Hallum decreased their price target on shares of Cardlytics from $70.00 to $50.00 and set a “hold” rating for the company in a research note on Tuesday, May 12th. TheStreet downgraded shares of Cardlytics from a “c-” rating to a “d” rating in a research note on Wednesday, March 18th. Zacks Investment Research downgraded shares of Cardlytics from a “hold” rating to a “sell” rating in a research note on Monday, June 15th. Finally, Bank of America downgraded shares of Cardlytics from a “buy” rating to an “underperform” rating and set a $26.00 price target for the company. in a research note on Tuesday, April 21st.

In other news, major shareholder Clifford Sosin purchased 47,700 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were purchased at an average price of $30.90 per share, for a total transaction of $1,473,930.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Thomas Evans sold 700 shares of the stock in a transaction that occurred on Monday, May 25th. The shares were sold at an average price of $67.48, for a total transaction of $47,236.00. Following the sale, the insider now owns 17,991 shares in the company, valued at approximately $1,214,032.68. The disclosure for this sale can be found here. In the last 90 days, insiders sold 215,759 shares of company stock worth $11,065,783. Corporate insiders own 6.50% of the company’s stock.

Several large investors have recently bought and sold shares of the company. American International Group Inc. grew its holdings in shares of Cardlytics by 3.2% during the fourth quarter. American International Group Inc. now owns 8,964 shares of the company’s stock valued at $563,000 after buying an additional 275 shares during the last quarter. Bank of Montreal Can grew its holdings in shares of Cardlytics by 3.6% during the fourth quarter. Bank of Montreal Can now owns 17,314 shares of the company’s stock valued at $1,088,000 after buying an additional 598 shares during the last quarter. Alliancebernstein L.P. grew its holdings in shares of Cardlytics by 4.3% during the first quarter. Alliancebernstein L.P. now owns 17,100 shares of the company’s stock valued at $598,000 after buying an additional 700 shares during the last quarter. Royal Bank of Canada grew its holdings in shares of Cardlytics by 30.2% during the first quarter. Royal Bank of Canada now owns 4,737 shares of the company’s stock valued at $166,000 after buying an additional 1,099 shares during the last quarter. Finally, Great West Life Assurance Co. Can purchased a new stake in shares of Cardlytics during the fourth quarter valued at approximately $83,000. Hedge funds and other institutional investors own 83.51% of the company’s stock.

Shares of NASDAQ:CDLX traded down $3.54 during midday trading on Friday, hitting $68.84. 1,963,611 shares of the stock traded hands, compared to its average volume of 707,157. The stock has a market capitalization of $1.95 billion, a PE ratio of -68.16 and a beta of 2.55. The business’s 50 day moving average is $67.39 and its two-hundred day moving average is $63.94. Cardlytics has a one year low of $23.50 and a one year high of $107.50.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.09. The firm had revenue of $45.51 million during the quarter, compared to the consensus estimate of $42.97 million. Cardlytics had a negative net margin of 11.08% and a negative return on equity of 19.42%. The company’s quarterly revenue was up 26.5% compared to the same quarter last year. During the same period in the prior year, the firm posted ($0.23) earnings per share. Sell-side analysts expect that Cardlytics will post -1.91 earnings per share for the current year.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Read More: What’s a Black Swan?

Analyst Recommendations for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.